Nogra Pharma and Torii Pharmaceutical Forge Groundbreaking Deal to Bring Revolutionary Acne Treatment to Japan

Nogra Pharma, a biotechnology company dedicated to creating groundbreaking therapies for immune-inflammatory-mediated diseases, has just announced a major licensing agreement with Torii Pharmaceutical Co., Ltd. Under the agreement, Nogra Pharma will be developing and bringing to market its NAC-GED-0507 treatment for acne vulgaris in Japan. This marks a significant step forward for Nogra Pharma in its mission to help people around the world live healthier lives.

Torii Pharmaceuticals has just secured exclusive development and commercialisation rights for NAC-GED-0507 in Japan in a deal whose financial terms remain undisclosed. This marks a huge milestone for the company as it further expands its operations across the country.

Nogra Pharma’s NAC-GED-0507 is a groundbreaking small molecule, selectively targeting the peroxisome proliferation-activated receptor γ (PPARγ) with a gel formulation designed for topical treatment of acne vulgaris. This innovative molecule works by tackling the root causes of acne, with its anti-inflammatory effects in both sebocytes and keratinocytes, its ability to regulate sebogenesis in sebocytes, its capability to restore keratinocytes proliferation and differentiation processes disrupted by pro-inflammatory cytokines, and its sebocytes differentiation induction properties.

The FDA and EMA have given their blessing to the late-stage clinical development plan, paving the way for a potential breakthrough in medical treatment. With the support of these two major regulatory bodies, the plan is now set to move forward and bring us closer to finding new and innovative solutions to healthcare challenges.

Acne vulgaris is an extremely common skin condition, affecting an estimated 85% of adolescents and young adults and 10% of the global population. Unfortunately, innovation in the space has been lacking for the past 25 years, with NAC-GED-0507 being the first treatment developed in that time that takes advantage of its pharmacological properties.

Leopoldo Zambeletti, Director of Nogra Pharma Ltd, expressed his enthusiasm for the agreement with Torii Pharmaceuticals, a testament to the company’s impressive scientific network and superior development and formulation capabilities. At Nogra Pharma, they are dedicated to creating novel therapies for immune-inflammatory-mediated diseases with high unmet medical need. This agreement takes them one step closer to achieving this goal.

We’re elated to be working on NAC-GED-0507, a groundbreaking new drug for acne that works via a novel mechanism of action, potentially becoming the first “disease-modifying agent” for millions of people affected by the condition! After decades of no new treatments, we are thrilled to be partnering with Torii, the experts in dermatology, to bring this revolutionary medication to life. With their help, we look forward to making a meaningful difference in the lives of those suffering from acne.

We are thrilled to join forces with Nogra and expand our portfolio of products to include NAC-GED-0507, which has the potential to revolutionize the treatment of dermatologic skin diseases. Goichi Matsuda, Representative Director, President and Chief Executive Officer of Torii, expressed his enthusiasm for the venture, emphasizing that the product has the potential to make a major impact in addressing the significant unmet need in this area.

We are excited to collaborate with Nogra to bring NAC-GED-0507 to the Japanese market as a new treatment option for acne sufferers. The development of NAC-GED-0507 is a revolutionary approach to tackling acne, and the promising clinical data has given us great confidence in its potential. We are hopeful that NAC-GED-0507 will bring relief to those struggling with acne.

Leave a Comment